Ultrasound BI-RADS might need some fine-tuning

Article

Breast cancers missed by mammography could have been misclassified as benign lesions by ultrasound to begin with, according to a study presented at the American Institute of Ultrasound in Medicine meeting in Orlando in June.

Breast cancers missed by mammography could have been misclassified as benign lesions by ultrasound to begin with, according to a study presented at the American Institute of Ultrasound in Medicine meeting in Orlando in June.

Dr. Dona J. Hills and colleagues from the Queens-Long Island Medical Group in New York found that 41 cancers matched current BI-RADS 2 and 3 assignments, based on their original ultrasound descriptions. They also found that 23 of the 41 had benign or negative findings on mammography. Physicians should be suspicious about ultrasound-detected lesions with atypical features, which can cause false negatives in mammography as well, Hills said.

"If we exclude suspicious findings from the 'probably benign' category and put them into a BI-RADS 4, we might not be underestimating as many cancers as we had underestimated before," she said.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.